Answers are grounded in this paper and cite their sources.
Gastrointestinal motility consists of highly coordinated neuromuscular processes, responsible for propagation of intraluminal contents through the gut (1-3). The complexity of the control of gastrointestinal motility has made the development of therapeutic agents for patients with motility disorders a substantial challenge. The most commonly employed agents for treating these patients are the prokinetics, which are drugs facilitating the transit of material through the digestive system (4). The prokinetic agents can be divided into four subclasses according to the mechanism of action: drugs with direct cholinergic activity; drugs with pronounced antidopaminergic properties; drugs that are agonists at neural 5-HT4 receptors; and drugs acting through gastrointestinal motilin receptors. This article focuses on cisapride, a relatively new prokinetic drug, and reviews its effects on gastrointestinal motility and its role in clinical practice. MECHANISMS OF ACTION Cisapride is a substituted piperinidyl benzamide chemically related to metoclopramide (Fig. 1) and devoid of antidopaminergic or direct cholinomimetic effects, which are characteristic of the previously developed substituted benzamides (5). Cisapride promotes motor activity at all levels of the gastro-intestinal tract. It increases the amplitude of the lower esophageal sphincter and esophageal body peristalsis and the force and incidence of gastric and antral contractions, it improves antroduodenal coordination to enhance gastric emptying, and it stimulates small-intestinal and colonic propulsion (6). Cisapride causes the release of acetylcholine from enteric neurons by stimulating a subpopulation of neural serotonin receptors (7). Early studies suggested that the prokinetic effect of cisapride might be due to antagonism of 5-HT3 receptors (8). However, other known 5-HT3 antagonists have relatively little effect on motor activity and propulsion along the gastrointestinal tract (8). Experimental studies in guinea pig ileum and colon have shown that cisapride activity is mainly mediated via 5-HT4 receptors and that acetylcholine release from varicosities on motor neurons of the myenteric plexus is promoted (9). As acetylcholine is the final mediator of the stimulating effects of cisapride, the latter can be blocked by atropine and other antimuscarinic drugs (8). Experimental studies have shown that cisapride enhances the amplitude of fast nicotinic excitatory postsynaptic potentials (EPSPs), which are components of the synaptic events in the enteric microcircuits (10). The effects of cisapride on the fast EPSPs can be antagonized by ICS 205-930, which blocks 5-HT4 receptors, but not by ondansetron, a 5-HT3 receptor antagonist (11). Fast EPSPs are responsible for rapid transfer and transformation of coded signals between elements of the integrated neural circuits and are mediated by acetylcholine acting at nicotinic-cholinergic postsynaptic receptors (11). There is experimental evidence that cisapride enhances the amplitude of nicotinic fast EPSPs by increasing nicotinic ganglionic transmission (12). Several experiments in animals clarified both the drug's mechanism of action and the contractile patterns evoked by its administration. Studies on smooth-muscle circular strips of the feline have shown that cisapride enhances the amplitude of electrically induced contractions in a dose-dependent fashion; pretreatment with tetrodotoxin or atropine abolishes this effect (13). In guinea pig gastroduodenal preparations and in conscious dogs, cisapride increases both the amplitude of antral motor waves and the number of antral waves followed by phasic doudenal activity. This combination results in an increased rate of gastric emptying of liquid and solid meals (5,14). In fasted dogs, intravenous cisapride stimulates motor activity of the upper-gastrointestinal tract and elicits contractile patterns similar to those recorded during the inter-digestive period, even though cisapride-induced contractions do not always migrate aborally through the small intestine (15,16). In the fed state, cisapride increases the amplitude of contractions and their length of spread along the small intestine (16). Cisapride has also been shown to induce tonic contractions of guinea pig right colon (13) and to enhance in conscious dogs ileocolonic motility and colonic transit (17,18). PHARMACOKINETICS Almost all the pharmacokinetic data are related to adults. There are few data on the pharmacokinetics of cisapride on children; nevertheless, there are no reasons to expect great differences from adults. After oral administration to human subjects, cisapride is almost completely absorbed, and only 4-6% of the oral dose is detected in stools. Peak plasma levels are reached within 2 h, and the absorbed dose is proportional to the amount administered. Steady-state plasma concentrations after multiple oral dosing are reached within 2-3 days. Absorption may be postponed or decreased because of delayed gastric emptying. Ingestion of cisapride 15 min before meals does not change the rate of absorption but increases the total amount absorbed. Under these conditions, the systemic availability of the drug is significantly higher (≈30%) than when the meal is given 2 h after administration of cisapride (19). Hypochlorhydria induced by H2 receptor antagonists in fasting subjects results in reduced systemic bioavailability of cisapride; however, the bioavailability is restored if cisapride is given 15 min before meals. Thus, cisapride should be given 15 min before meals to ensure optimal absorption under all conditions of gastric acidity. Cisapride is extensively bound (98%) to plasma protein, and albumin is the main binding protein. It undergoes an extensive metabolism by N-dealkylation and aromatic hydroxylation, metabolites have negligible pharmacologic activity compared with the parent compound and are excreted in the urine and feces. The drug has a half-life of 7-10 h, which is prolonged in elderly subjects and in those with impaired liver function (20). After intramuscular dosing, absorption is rapid and complete, and peak concentrations in the plasma are reached within 10-30 min. After rectal administration, there is a rapid rise in plasma concentration, and absorption is sustained over ≥8 h. The recommended oral dose in infants and children is 0.1-0.3 mg/kg every 6-8 h (suspension); the adult dose of 10 mg three times a day should not be exceeded. Because a liquid preparation of cisapride is not currently available in the United States, recently an extemporaneously prepared cisapride suspension from crushed tablets has been proposed for infants and patients unable to swallow the tablets (21). This extemporaneous suspension is formulated with propylene glycol to enhance solubility and is buffered with sodium bicarbonate to give a pH between 6.5 and 7.5; this formulation has been shown to be stable for 3 weeks. At a daily dose of 30 mg in adults, cisapride has no effect on microsomal liver enzymes; however, enhanced gastrointestinal motility due to cisapride may accelerate the absorption rate of other substances, such as diazepam, cimetidine, acetaminophen, alcohol, and oral anticoagulants. Excretion of cisapride into breast milk is very limited (≈0.1% of the original dose), and maternal ingestion of the drug is unlikely to affect the nursing infant. EFFECTS ON THE ESOPHAGUS AND ESOPHAGEAL MOTILITY DISORDERS Studies in children with gastroesophageal reflux (GER) corroborate findings in adult patients. In 14 children (ages 2-38 months) with GER disease, cisapride given intravenously at a dose of 0.15 mg/kg significantly increased lower esophageal sphincter pressure (LESP) and the amplitude and duration of esophageal peristaltic waves (22); LESP rose 15 min after the infusion, reaching a peak value at 60 min (32.4 ± 10 mm Hg vs. baseline 14.5 ± 3.08, p < 0.01) and remaining significantly elevated through-out a 90-min period. The maximum amplitude of peristaltic waves also occurred at 60 min (67.1 ± 35.7 vs. baseline 39.7 ± 23.7, p < 0.01). The duration of peristaltic waves was also increased by in-travenous cisapride, with the peak occurring 60 min after infusion (3.51 ± 1.09 s vs. baseline 2.8 ± 0.72 s, p < 0.05). While the effects on LESP have been corroborated in many studies, cisapride's effects on esophageal peristalsis are controversial. Depending on testing conditions, an increase in contraction amplitude and duration or no change has been documented (23). Although clinical symptoms and side effects of GER disease depend on acid peptic injury of esophageal mucosa, reflux events occur as a consequence of phasic or prolonged LESP failure, furthermore, defective esophageal peristalsis and delayed gastric emptying can contribute to the development of esophagitis and enhance the incidence and volume of reflux events, respectively. Therefore, cisapride should be efficacious for treating GER disease, since it influences motility variables implicated in the pathogenesis of GER disease (4). A growing body of evidence emphasizes the efficacy of cisapride in the treatment of GER in infants and children, although few data come from well-controlled double-blind studies (see Table 1). When given to infants and toddlers with uncomplicated GER disease for 8 weeks at a dose of 0.3 mg/kg/dose t.i.d., cisapride proved more effective than placebo in relieving symptoms, reducing esophageal acid exposure, and improving esophagitis (24). Good relief of symptoms and a decreased number of prolonged episodes of GER were achieved in 29 infants who participated in a double-blind study of the administration of cisapride (0.2 mg/kg four times daily) for 13-16 days (25). In a controlled study in 14 infants and toddlers with uncomplicated GER, oral cisapride given for 4 weeks both improved symptoms and lessened intraesophageal acid exposure to a greater extent than positioning or dietary measures (22). There are few clinical studies that have compared the effect of cisapride with that of other drugs. Cisapride, given at a dose of 0.8 mg/kg/day for 4 weeks, was as effective as a combination of Gaviscon and Carobel (a thickening agent) in improving both intraesophageal pH variables and clinical symptoms (26). In two double-blind studies, cisapride (0.2-0.6 mg/kg/day) was as effective as the same dose of metoclopramide in improving symptoms of reflux, but cisapride induced a more rapid symptomatic improvement than metoclopramide (27,28). In a double-blind randomized study of 17 infants, cisapride (0.2 mg/kg four times daily) was as effective as cimetidine (5 mg/kg four times daily) in combination with Gaviscon in improving intraesophageal pH scores after 6 weeks (29). Other clinical trials have been conducted to examine the efficacy of cisapride in children with GER disease complicated by chronic pulmonary disease. Cisapride has been shown to be superior to placebo in a double-blind crossover trial in 14 patients with pathologic GER and chronic bronchopulmonary disease (30); the drug, given at a dose of 0.3 mg/kg before the start of pH monitoring, followed by three doses given at 4-h intervals (0.15 mg/kg), was effective in lowering the intraesophageal pH scores both during daytime and nocturnal recording periods. A marked reduction in respiratory symptoms, including bronchospasm and stridor, was seen in concert with the improvement in intraesophageal pH scores (31-33). Vandenplas et al. have evaluated the effect of cisapride (0.2 mg/kg four times daily) in an open trial in 22 infants (4-26 weeks old) affected by GER associated with apnea and sleep disturbances (34). Eight of the patients had had at least one episode of ALTE (apparent life-threatening event). Continuous intraesophageal pH monitoring was performed before and after 13-16 days of treatment with cisapride; reflux parameters declined significantly during treatment, and the disrupted sleep pattern improved significantly or disappeared in all infants. Children with central nervous system (CNS) disease are prone to severe GER disease and require an intensive therapeutic program. A group of seven children with neurodevelopmental has been with cisapride and compared with a group of infants with GER but no who were There was no change in the parameters by pH monitoring and no improvement in gastrointestinal symptoms in the impaired patients with GER improved both in the pH variables and in Thus, the efficacy of cisapride in treating GER in the has not been Studies in with esophagitis have shown that a combination of cisapride mg or mg with antagonists increases the rate compared with a combination of cisapride with placebo or to Other studies in have shown that cisapride mg daily) the of previously reflux esophagitis more than placebo The group on GER of the for and recommended the of cisapride in uncomplicated of symptomatic GER in to positioning and dietary cisapride was also recommended in combination with for children with to severe esophagitis In cisapride is currently the prokinetic for patients with reflux disease, or not have However, studies in children are that cisapride with drugs known to be effective in severe such as and has been to the of GER in patients with Several studies have shown that treatment of patients with cisapride has been in esophageal acid exposure, improving reflux symptoms, and respiratory OF AND DISORDERS is a motor of the that consists of an impaired transit of intraluminal from the to the It can be an or associated with other motility disorders Several in motility of the antroduodenal to delayed gastric fed antral and phasic activity with The treating gastric and motor disorders with cisapride is on the drug's to increase the amplitude of antral contractions and the between antral and contractions motor disorders and are in patients with symptoms of and This clinical is more commonly in than in children and is known as or Cisapride is to accelerate gastric emptying by increasing both the number and amplitude of antral contractions that into the motor it has been shown that patients with had waves than After administration of intravenous cisapride, there was an increase in the number of waves as as in the gastric emptying rate of solid A controlled double-blind study in with an of gastric emptying for both and documented by a of gastric emptying occurred in the of the that it is an of action of There are few studies on the of cisapride in children with gastric or gastroduodenal motor infants with and gastroesophageal reflux months) were with cisapride given in an open at a dose of 0.3 for 8 weeks. had been documented by of the gastric Cisapride lessened final gastric emptying and the antral at all the study there was also a between the improvement in the gastric motor variables and that in the esophageal exposure acid children with chronic symptoms of both double-blind intravenous and oral treatment with cisapride with monitoring of antroduodenal gastric emptying of a liquid and symptoms cisapride induced a very motor pattern at the antroduodenal by a greater number and amplitude of contractions and by a of waves aborally when compared with baseline At the of the treatment period, symptoms improved both in the cisapride and in the placebo however, patients on cisapride a greater in the symptomatic than the placebo and only cisapride in a gastric emptying administration of oral cisapride also gastric activity recorded by in children affected by and In a 10 children with and gastric were for 8 weeks with oral cisapride at a dose of At the of the trial there was a marked improvement in furthermore, a reduction of gastric emptying and gastric was recorded Cisapride gastric activity by in patients with However, in with severe from cisapride at a dose of mg three times a day significantly gastric emptying of a solid meal but to symptoms A study three children with and symptoms chronic after three had documented by and antral by patients had in with cisapride in improvement of symptoms in one gastric emptying also commonly in patients with who of and that can be by or Cisapride given to with by intravenous or mg improved gastric emptying of a meal and increased the amplitude of contractions in studies but not in Thus, there is evidence that cisapride may be efficacious in treatment of of patients with It that cisapride may be in patients with but there is a for studies in patients with due to or systemic disorders or However, improvement in motility does not as symptoms more from than from motility patterns The effects of cisapride on symptoms and gastro-intestinal motility have also been in children with chronic In an both intravenous and oral cisapride amplitude and number of contractions in the in of in two patients with amplitude waves the drug increased the of contractions and of a 3 of the motor However, in a study in children, the effect of cisapride on gastric emptying of a liquid meal and on gastrointestinal motility was Cisapride not the in and not significantly increase the of It increase the motility but had no effect on the antral motility it not induce 3 of the motor in patients in it was during the placebo The drug not the marked in gastric emptying. A study of a group of children with chronic has two main variables that the therapeutic to the drug A to cisapride was by the of motor and as as by the of with a than those with a of In children with motor was in to and cisapride was patients 17 were and seven were to from total to or from to oral The study the that a therapeutic to cisapride can be by a of and findings in The most severe of motility in chronic and administration of prokinetic agents is Cisapride is the prokinetic drug that has shown a efficacy in patients with in those in to of the by of extensive at of motor at and of findings of (6). with are more to cisapride than those with the of the (8). In oral cisapride might not be absorbed because of severe gastric and in these the drug may be given through a with absorption In patients on total cisapride administration be in the of and and be with administration of results from impaired contractions and transit through the colon or from a mechanism of at the of the The latter mechanism in Cisapride has been shown to a marked prokinetic effect on colonic transit in subjects The effects of cisapride on colonic motility and transit were in 10 adult patients and transit were before and after weeks of cisapride administration Cisapride improved symptoms in patients who previously had shown a increase in colonic it was not effective in patients with no increase in colonic A had shown that cisapride enhance the by increasing conscious rectal and by rectal It is also that cisapride may the of the in the and as a consequence of a reduced transit Table 2 The results of a small number of studies in patients with chronic to a role for cisapride in the treatment of this In adult patients with chronic the effect of cisapride on and was in a randomized double-blind Cisapride, but not significantly increased < was decreased more by cisapride < 0.01) than by placebo < 0.05). The most pronounced effect of treatment was on Other clinical trials in these findings children (ages with to of were with cisapride at an dose of mg/kg/dose to a maximum of mg/kg/dose or 10 mg Cisapride treatment weeks ± there was no change in but patients the in of 10 and the number of episodes declined in the other two The effects of cisapride mg/kg/day) have also been in a double-blind in a group of children with total gastrointestinal transit and motility variables were evaluated Cisapride increased < and a in the volume to the the conscious rectal and the gastrointestinal transit other prokinetic data from studies that cisapride be an effective in treating patients with treatment of consists of given after of the rectal through Cisapride may be if is to doses of and may be of value in reducing however, clinical efficacy of the drug in due to of the colon is colonic motility patterns that are to the administration of cisapride have not been in patients. In a double-blind crossover the effect of a trial of cisapride was in 17 patients with Cisapride was more effective than placebo in reducing < and and < 0.05). cisapride treatment, patients to be However, no differences between cisapride and placebo was in pulmonary and and of Cisapride may be effective in treating adult patients were given intravenous cisapride or placebo on the day of and the dose was every h the Cisapride induced of motility in the as by the of The study not the length of was or patients The efficacy and the side effect of cisapride have been in infants causes for gastrointestinal infants were and Cisapride was given as a infusion through the at doses of 0.15 mg/kg every 6 h, 30 min before developed in only four patients. In three of it was before administration of cisapride, and the effect of cisapride not be after the start of treatment was in only one and was Because of the of GER and the of delayed the of cisapride in with gastric and to be Cisapride is the prokinetic for treating the of gastrointestinal motility disorders in other prokinetic it has a antidopaminergic or direct cholinomimetic effects (6). Cisapride is devoid of effects and has a very incidence of central nervous system effects (6). effects, which can be from its pharmacologic have clinical and and In the of studies, the incidence of effects in patients was similar to and the incidence of events not to be related to the dose of Cisapride has been in of patients because of or compared with of patients on In studies the incidence of events was similar to In children with cisapride the are of a similar to those in adults, and the incidence is not increased and has been in with cisapride; these be due to increased cholinergic activity Several of the of cisapride for treating GER disease in children therapeutic trials including children with the most severe of esophagitis are The role of the drug in combination with agents in esophagitis should also be It is also administration of cisapride can be efficacious in treating chronic esophagitis of Cisapride to be of limited value in children with reflux due to in these patients cisapride should be given for in with doses of drugs. Cisapride is also the prokinetic for gastrointestinal motility Several its in improving gastric emptying and gastroduodenal both in patients with gastrointestinal symptoms and in patients with GER the drug can also be effective in symptoms of only a few studies have evaluated the of cisapride in gastrointestinal motility clinical trials should be performed with and of motility results of cisapride administration be related to the motility patterns recorded in the patients. Cisapride might be in to other prokinetic such as metoclopramide and to combination has a role in gastrointestinal motility prokinetic drugs with pharmacologic of action might have oral cisapride has been in with and and as treatment of esophagitis to and symptomatic There are only a few on oral of cisapride in The drug was given to children with chronic for a weeks and to a of children with chronic for chronic treatment with other prokinetics, the effect of chronic administration of cisapride on gastric emptying and symptoms is for and does not to (6). In trials on months) treatment with cisapride of adult GER disease, the incidence of effects from 8 to to with The most events were such gastrointestinal as and the treatment was in of the patients. in or variables as as were The effects of cisapride in improving motility and transit in chronic is to the complexity of the disease the disease a trial of cisapride is for most children with and the drug is more effective if of motor and of gut is a chronic cisapride should be for periods. controlled studies on oral cisapride treatment in children with chronic are The is to for and at improving the of metoclopramide and cisapride 3
No takes yet. Share an insight, caveat, or question.
Salvatore Cucchiara (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: